Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) rose in Tuesday trading after dropping 19.5% on Monday.
Innovate Biopharmaceuticals reported that it had entered into a collaboration on larazotide's effect on improving microbiome of children with EED with the University of Virginia School of Medicine.
The company, headquartered in Raleigh, North Carolina, announced today it has agreed to collaborate with James P. Nataro, the Benjamin Armistead Shepherd Professor and Chair, Director of Children's Services, UVA Children's Hospital of the University of Virginia School of Medicine, whose research is focused on the study of enteric bacteria and their roles in health and disease.
Dr. Nataro commented, "I am excited by this collaboration. Abnormalities of intestinal permeability underlie a host of human diseases such as environmental enteric dysfunction, known as EED.
"EED is a disorder that afflicts millions of children around the world, leading to growth faltering, cognitive delay and impaired resistance to infection.”
Environmental enteric dysfunction is a common malady afflicting millions of children who live in impoverished circumstances around the world.
EED is characterized by intestinal inflammation and abnormal permeability, and results in growth faltering and malnutrition. Although the precise cause of EED remains elusive, gut bacteria are thought to play a role in its pathogenesis.
Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory diseases. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking
Shares gathered 20 cents, or 3.6%, to $5.68
Related Stories
